Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05379972 · ClinicalTrials.gov registry record · Phase 2
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
A Phase 2 study of Gastric Cancer and GastroEsophageal Cancer, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 4
- Study locations
NCT05379972 is a Phase 2 study of Gastric Cancer and GastroEsophageal Cancer that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 9 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT05379972, a Phase 2 study of Gastric Cancer and GastroEsophageal Cancer, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is an open-label, phase II study with a safety lead-in to assess the response rate of induction olaparib and stereotactic beam radiotherapy (SBRT) followed by combination olaparib/pembrolizumab in patients with metastatic gastric and GEJ cancers after at least one of therapy.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- RADIATION Stereotactic Body Radiation Therapy
- DRUG Olaparib
Study Locations (4)
Colorado
- University of Colorado Health - Aurora
- UCHealth Memorial Hospital Central - Colorado Springs
- UCHealth Memorial Hospital North - Colorado Springs
- UCHealth Highlands Ranch Hospital - Highlands Ranch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-01-12 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05379972
The ClinicalTrials.gov registry entry for NCT05379972 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (97% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05379972 reports 4 study locations spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT05379972 about?
NCT05379972 is a clinical study titled "Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers". This study is an open-label, phase II study with a safety lead-in to assess the response rate of induction olaparib and stereotactic beam radiotherapy (SBRT) followed by combination olaparib/pembrolizumab in patients with metastatic gastric and GEJ cancers after at least one of therapy.
What is the current status of trial NCT05379972?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2023-01-12. Estimated completion is 2028-12.
What conditions does trial NCT05379972 study?
This clinical trial studies the following conditions: Gastric Cancer, GastroEsophageal Cancer.
What interventions are being tested in trial NCT05379972?
The interventions under investigation include: Pembrolizumab (DRUG), Stereotactic Body Radiation Therapy (RADIATION), Olaparib (DRUG).
Who is sponsoring clinical trial NCT05379972?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05379972 being conducted?
This trial has 4 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.